Absorption, bioavailability, and partner transfer of estradiol from a topical emulsion

Pharmacotherapy

Volumn 28, Issue 6, 2008, Pages 712-718

  Taylor, Maida B ^a   Gutierrez, Maria J ^b  

^a Esprit Pharma   (United States)

^b CNS Clinical Trials   (United States)

Author keywords

Absorption; Bioavailability; Estradiol topical emulsion; Estrasorb; Estrogen therapy; Hormone replacement therapy; Micellar nanoparticle emulsion; Partner transfer

Indexed keywords

ESTRADIOL; ESTRONE; ESTRONE SULFATE; FOLLITROPIN; NANOPARTICLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; EMULSION; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; POSTMENOPAUSE; SPOUSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, TOPICAL; ADULT; AGED; BIOLOGICAL AVAILABILITY; EMULSIONS; ESTRADIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMENOPAUSE; SKIN;

EID: 47149089618     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.6.712     Document Type: Article

References (25)

1. Nichols KC, Schenkel L, Benson H. 17 beta-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv 1984;39(4):230-45.
2. Dickerson J, Bressler R, Christian CD, Hermann HW. Efficacy of estradiol vaginal cream in postmenopausal women. Clin Pharmacol Ther 1979;26(4):502-7.
3. Greendale GA, Judd HL. The menopause: health implications and clinical management. J Am Geriatr Soc 1993;41(4):426-36.
4. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11(1):11-33.
5. Bhavnani BR, Nisker JA, Martin J, Aletebi F, Watson L, Milne JK. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Investig 2000;7(3):175-83.
6. Jarvinen A, Nykanen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32(2):103-13.
7. Jarvinen A, Backstrom AC, Elfstrom C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001;38(2):189-96.
8. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9suppl):18S-24.
9. Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. Maturitas 2001;40(3):203-9.
10. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Arzneimittelforschung 1996;46(8):766-73.
11. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006;13(2):222-31.
12. Boxenbaum H, Muenz L, Group ES. Pharmacokinetics of Estrasorb, a topical lotion for treatment of postmenopausal vasomotor symptoms [abstract]. J Soc Gynecol Investig 2002;9(1 suppl):238A.
13. Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. Virilization of young children after topical androgen use by their parents. Pediatrics 2004;114:282-4.
14. Esprit Pharma, Inc. Estrasorb (estradiol topical emulsion) prescribing information. East Brunswick, NJ; 2003. Available from http://www.fda.gov/cder/foi/label/2003/21371_estrasorb_lbl.pdf. Accessed November 10, 2006.
15. Wu CH, Lundy LE. Radioimmunoassay of plasma estrogens. Steroids 1971;18(1):91-111.
16. Neely EK, Hintz RL, Wilson DM, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127(1):40-6.
17. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6(6):539-46.
18. U.S. Food and Drug Administration. Center for Drug Evaluation and Research approval package for: application number 21-166. Clinical pharmacology and biopharmaceutics review. 2004. Available from http://www.fda.gov/cder/foi/ nda/ 2004/21166_Estrogel%20Gel_biopharmr.pdf. Accessed November 16, 2006.
19. Zborowski J, Snabes M, Simes S. Evaluation of subject to partner transfer of Bio-E-Gel® (transdermal estradiol gel) [abstract]. Menopause 2006;13(6):1018.
20. Blacker C, Brion N, Caulin F, et al. Plasma concentration of estradiol after transdermal administration of Systen®50 (Evorel®) or Menorest®50. Clin Drug Invest 1996;11(6): 339-46.
21. Guichard JP, Sauron R, Jones AB. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. J Clin Pharmacol 1999;39(8):811-16.
22. Reginster JY, Albert A, Deroisy R, et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. Maturitas 1997;27(2):179-86. (Erratum in Maturitas 1997;28(2):193-5.)
23. Esprit Pharma, Inc. Estrasorb data on file, study E98-1 (E2002-2). East Brunswick, NJ; 2003.
24. Mazer N, Fisher D, Fischer J, Cosgrove M, Bell D, Eilers B. Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J Sex Med 2005;2(2):3227-34.
25. Simon JA, Wysocki S, Goldstein S, Stuenkel CA. A clinical review and discussion of the efficacy and safety of a new transdermal form of hormone therapy. Menopause Manage 2006;15(5suppl):1-15.